Search Results

There are 53337 results for: content related to: Hypogonadism related to crizotinib therapy

  1. You have free access to this content
    ALK-positive non–small cell lung cancer: Mechanisms of resistance and emerging treatment options


    Volume 120, Issue 16, August 15, 2014, Pages: 2392–2402, Conor E. Steuer and Suresh S. Ramalingam

    Version of Record online : 22 MAY 2014, DOI: 10.1002/cncr.28597

  2. Current Status of Targeted Therapy for Anaplastic Lymphoma Kinase–Rearranged Non–Small Cell Lung Cancer

    Clinical Pharmacology & Therapeutics

    Volume 95, Issue 1, January 2014, Pages: 15–23, B Solomon, KD Wilner and AT Shaw

    Version of Record online : 19 DEC 2013, DOI: 10.1038/clpt.2013.200

  3. Development of crizotinib, a rationally designed tyrosine kinase inhibitor for non-small cell lung cancer

    International Journal of Cancer

    Volume 140, Issue 9, 1 May 2017, Pages: 1945–1954, Candice C. Poon and John J. Kelly

    Version of Record online : 20 JAN 2017, DOI: 10.1002/ijc.30533

  4. You have full text access to this OnlineOpen article
    Complex renal cysts associated with crizotinib treatment

    Cancer Medicine

    Volume 4, Issue 6, June 2015, Pages: 887–896, Patrick Schnell, Cynthia H. Bartlett, Benjamin J. Solomon, Vanessa Tassell, Alice T. Shaw, Tommaso de Pas, Soo-Hyun Lee, Geon Kook Lee, Kaoru Tanaka, Weiwei Tan, Yiyun Tang, Keith D. Wilner, Allan Safferman and Ji-Youn Han

    Version of Record online : 10 MAR 2015, DOI: 10.1002/cam4.437

  5. Targeting ALK Rearrangements

    Lung Cancer, Fourth Edition

    Justin F. Gainor, Alice T. Shaw, Pages: 541–556, 2014

    Published Online : 4 APR 2014, DOI: 10.1002/9781118468791.ch35

  6. You have full text access to this Open Access content
    Echinoderm microtubule-associated protein-like 4–anaplastic lymphoma kinase-targeted therapy for advanced non-small cell lung cancer: Molecular and clinical aspects

    Cancer Science

    Volume 103, Issue 8, August 2012, Pages: 1391–1396, Isamu Okamoto and Kazuhiko Nakagawa

    Version of Record online : 17 JUN 2012, DOI: 10.1111/j.1349-7006.2012.02327.x

  7. You have full text access to this OnlineOpen article
    Sufficiency of Single-Arm Studies to Support Registration of Targeted Agents in Molecularly Selected Patients with Cancer: Lessons from the Clinical Development of Crizotinib

    Clinical and Translational Science

    Volume 9, Issue 2, April 2016, Pages: 63–73, P Selaru, Y Tang, B Huang, A Polli, KD Wilner, E Donnelly and DP Cohen

    Version of Record online : 1 MAR 2016, DOI: 10.1111/cts.12388

  8. You have free access to this content
    Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer


    Volume 118, Issue 21, 1 November 2012, Pages: 5302–5309, Andrew J. Weickhardt, Micol S. Rothman, Smita Salian-Mehta, Katja Kiseljak-Vassiliades, Ana B. Oton, Robert C. Doebele, Margaret E. Wierman and D. Ross Camidge

    Version of Record online : 4 APR 2012, DOI: 10.1002/cncr.27450

  9. Optimizing Treatment for Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer

    Clinical Pharmacology & Therapeutics

    Volume 101, Issue 5, May 2017, Pages: 625–633, I Dagogo-Jack, AT Shaw and GJ Riely

    Version of Record online : 17 MAR 2017, DOI: 10.1002/cpt.653

  10. You have full text access to this OnlineOpen article
    Crizotinib versus platinum-based double-agent chemotherapy as the first line treatment in advanced anaplastic lymphoma kinase-positive lung adenocarcinoma

    Thoracic Cancer

    Volume 7, Issue 1, January 2016, Pages: 3–8, Quan Zhang, Na Qin, Jinghui Wang, Jialin Lv, Xinjie Yang, Xi Li, Jingying Nong, Hui Zhang, Xinyong Zhang, Yuhua Wu and Shucai Zhang

    Version of Record online : 23 APR 2015, DOI: 10.1111/1759-7714.12264

  11. You have full text access to this OnlineOpen article
    Is there a progression-free survival benefit of first-line crizotinib versus standard chemotherapy and second-line crizotinib in ALK-positive advanced lung adenocarcinoma? A retrospective study of Chinese patients

    Cancer Medicine

    Volume 5, Issue 6, June 2016, Pages: 1013–1021, Shaohua Cui, Yizhuo Zhao, Lili Dong, Aiqin Gu, Liwen Xiong, Jialin Qian, Wei Zhang, Yanjie Niu, Feng Pan and Liyan Jiang

    Version of Record online : 16 FEB 2016, DOI: 10.1002/cam4.659

  12. You have full text access to this OnlineOpen article
    Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK

    Cancer Medicine

    Volume 4, Issue 7, July 2015, Pages: 953–965, Diletta Fontana, Monica Ceccon, Carlo Gambacorti-Passerini and Luca Mologni

    Version of Record online : 26 FEB 2015, DOI: 10.1002/cam4.413

  13. You have free access to this content
    Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein

    British Journal of Pharmacology

    Volume 166, Issue 5, July 2012, Pages: 1669–1683, Wen-jing Zhou, Xu Zhang, Chao Cheng, Fang Wang, Xiao-kun Wang, Yong-ju Liang, Kenneth Kin Wah To, Wang Zhou, Hong-bing Huang and Li-wu Fu

    Version of Record online : 21 JUN 2012, DOI: 10.1111/j.1476-5381.2012.01849.x

  14. You have free access to this content
    Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients


    Volume 119, Issue 13, 01 July 2013, Pages: 2383–2390, Andrew J. Weickhardt, Robert C. Doebele, W. Thomas Purcell, Paul A. Bunn, Ana B. Oton, Micol S. Rothman, Margaret E. Wierman, Tony Mok, Sanjay Popat, Julie Bauman, Jorge Nieva, Silvia Novello, Sai-Hong Ignatius Ou and D. Ross Camidge

    Version of Record online : 12 APR 2013, DOI: 10.1002/cncr.28089

  15. You have full text access to this OnlineOpen article
    Crizotinib-Resistant Mutants of EML4-ALK Identified Through an Accelerated Mutagenesis Screen

    Chemical Biology & Drug Design

    Volume 78, Issue 6, December 2011, Pages: 999–1005, Sen Zhang, Frank Wang, Jeffrey Keats, Xiaotian Zhu, Yaoyu Ning, Scott D. Wardwell, Lauren Moran, Qurish K. Mohemmad, Rana Anjum, Yihan Wang, Narayana I. Narasimhan, David Dalgarno, William C. Shakespeare, Juan J. Miret, Tim Clackson and Victor M. Rivera

    Version of Record online : 31 OCT 2011, DOI: 10.1111/j.1747-0285.2011.01239.x

  16. You have full text access to this OnlineOpen article
    Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors

    Cancer Science

    Volume 108, Issue 1, January 2017, Pages: 53–60, Hirokazu Taniguchi, Shinji Takeuchi, Koji Fukuda, Takayuki Nakagawa, Sachiko Arai, Shigeki Nanjo, Tadaaki Yamada, Hiroyuki Yamaguchi, Hiroshi Mukae and Seiji Yano

    Version of Record online : 30 DEC 2016, DOI: 10.1111/cas.13111

  17. You have free access to this content
    Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar

    International Journal of Cancer

    Volume 134, Issue 6, 15 March 2014, Pages: 1484–1494, Seng Chuan Tang, Luan N. Nguyen, Rolf W. Sparidans, Els Wagenaar, Jos H. Beijnen and Alfred H. Schinkel

    Version of Record online : 3 OCT 2013, DOI: 10.1002/ijc.28475

  18. You have free access to this content
    Treatment of ALK-rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context

    Asia-Pacific Journal of Clinical Oncology

    Volume 13, Issue S3, August 2017, Pages: 3–13, M. Itchins, P.L. Chia, S.A. Hayes, V.M. Howell, A.J. Gill, W.A. Cooper, T. John, P. Mitchell, M. Millward, S.J. Clarke, B. Solomon and N. Pavlakis

    Version of Record online : 10 AUG 2017, DOI: 10.1111/ajco.12754

  19. You have free access to this content
    Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib


    Volume 120, Issue 5, 1 March 2014, Pages: 664–674, Evelyn M. Brosnan, Andrew J. Weickhardt, Xian Lu, Delee A. Maxon, Anna E. Barón, Michel Chonchol and D. Ross Camidge

    Version of Record online : 20 NOV 2013, DOI: 10.1002/cncr.28478

  20. Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects

    The Journal of Clinical Pharmacology

    Volume 55, Issue 1, January 2015, Pages: 104–113, Huiping Xu, Melissa O'Gorman, Tanya Boutros, Nicoletta Brega, Constantino Kantaridis, Weiwei Tan and Akintunde Bello

    Version of Record online : 10 JUL 2014, DOI: 10.1002/jcph.356